Memic has headquarters in Tel Aviv, Israel as well as a wholly owned subsidiary in Fort Lauderdale, FL established for global customer services
TEL AVIV, Israel and FORT LAUDERDALE, Fla., March 1, 2021 Memic, a medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization of its Hominis® robot-assisted surgical platform for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy. The De Novo authorization is supported by clinical data from procedures using the Hominis system on a variety of patients in Belgium and Israel with Drs. Jan Baekelandt and Lior Lowenstein, respectively.
“This FDA authorization represents a significant advance in the world of robot-assisted surgery and fulfills an unmet need in the world of robotic gynecological surgery,” said Professor Jan Baekelandt, MD, PhD, a gynecologist at Imelda Hospital in Bonheiden, Belgium, who performed the first hysterectomy using the Hominis system in November 2018. “Research shows vaginal hysterectomy provides optimal clinical benefits to patients including reduced pain, recovery time and rates of infection but in most countries the incidence of vaginal hysterectomy is decreasing. In addition, transvaginal approaches result in no visible scars, which is very important to the gynecological patient. Hominis is the only robot specifically developed for transvaginal surgery and is therefore small and flexible enough to perform surgery through a small incision.”
The Hominis (Latin for humanoid) system is the first and only FDA-authorized surgical robotic platform that features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation. The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon’s arms, with shoulder, elbow and wrist joints. Multiple instruments can be introduced to the body through a single portal and the 360-degree articulation offers obstacle avoidance as well as optimal access and working angles. In addition to these features, the system will be sold at a significantly lower price compared to other marketed robotic surgery systems, potentially allowing more medical facilities including hospitals and ambulatory surgical centers to access and adopt surgical robotics.
The company plans to pursue general surgery and transluminal indications for the Hominis platform and is developing artificial intelligence (AI)-enabled features to support all its surgical indications.
“We are pleased to receive FDA De Novo authorization of our Hominis system, which offers a small, cost-effective and less invasive option over current robotic instruments limited to straight shaft and single wrist designs and controlled with large, complex and expensive equipment,” said Dvir Cohen, CEO of Memic. “This authorization is also just the beginning; it opens the door for our novel system to expand to additional indications that, until now, have been off-limits to robot-assisted surgery.”
“We believe the Hominis surgical system represents the most significant advancement in robotic soft tissue surgery in the last 20 years and will deliver great benefit to patients and their healthcare providers,” added Maurice R. Ferré, MD, chairman of the board at Memic and founder of MAKO Surgical, Inc.
Approximately 600,000 hysterectomies are performed annually in the U.S.1 The transvaginal approach is well documented as resulting in better clinical benefits, including less patient pain and scarring, shorter recovery times and reduced infection rates, compared to other approaches to hysterectomy.2 But surgeons use the transvaginal approach in only 16 percent3 of hysterectomies due to anatomical barriers and accessibility challenges.4,5 In a recent clinical study using the Hominis system to perform 30 hysterectomies, 100 percent were completed successfully with the transvaginal approach with no device-related adverse events or intraoperative complications.
Memic has headquarters in Tel Aviv, Israel as well as a wholly owned subsidiary in Fort Lauderdale, FL established for global customer services, professional education and sales, marketing and clinical research. Memic’s leadership team has more than 70 years of combined experience in the surgical robotic arena. Its chairman of the board is Maurice R. Ferré, MD, founder and CEO of Mako Surgical, Inc. For more information, visit https://www.memicmed.com/.
- Whiteman M, Hillis S, Jamieson D, et al., “Inpatient hysterectomy surveillance in the United States 2000-2004,” Am J Obstet Gynecol 2008; 198(1): 34. doi: https://doi.org/10.1016/j.ajog.2007.05.039.
- Aarts JWM, Nieboer TE, Johnson N, Tavender E, Garry R, Mol BWJ, Kluivers KB. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2015. 2015 Aug 12;2015(8):CD003677. doi: 10.1002/14651858.CD003677.pub5.
- Luciano AA, Luciano DE, Gabbert J, Seshadri-Kreaden U. The impact of robotics on the mode of benign hysterectomy and clinical outcomes. Int J Med Robot. 2016 Mar;12(1):114-24. doi: 10.1002/rcs.1648. Epub 2015 Mar 4. PMID: 25753111.
- Committee Opinion No 701: Choosing the Route of Hysterectomy for Benign Disease. Obstet Gynecol. 2017 Jun;129(6):e155-e159. doi: 10.1097/AOG.0000000000002112.
- Wu JM, Wechter ME, Geller EJ, Nguyen TV, Visco AG. Hysterectomy rates in the United States, 2003. Obstet Gynecol. 2007 Nov. 110(5):1091-5 (ISSN: 0029-7844).
By PR Newswire